Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-08046052 in Advanced Solid Tumors
NCT05983133Phase 1Terminated
- Sponsor
- Pfizer
- Start
- Nov 2023
- Primary completion
- Apr 2026
- Modality
- Bispecific Antibodies, Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of PF-08046052 in colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC) and 1 more, sponsored by Pfizer. Primary endpoints: Adverse Events at 1 year, Laboratory abnormalities at 1 year and 2 more. Started Nov 2023; status: terminated.
02
Drugs
PF-08046052
03
Conditions
colorectal cancer (CRC)non-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05983133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05983133.